We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

159 hedge funds and large institutions have $1.24B invested in Portola Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 64 increasing their positions, 46 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more call options, than puts

Call options by funds: $4.22M | Put options by funds: $1.78M

39% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 46

15% more capital invested

Capital invested by funds: $1.08B → $1.24B (+$158M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

5% less funds holding

Funds holding: 167159 (-8)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

Holders
159
Holders Change
-8
Holders Change %
-4.79%
% of All Funds
4.24%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
22
Increased
64
Reduced
46
Closed
28
Calls
$4.22M
Puts
$1.78M
Net Calls
+$2.45M
Net Calls Change
-$21.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Temasek Holdings
1
Temasek Holdings
Singapore
$155M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$149M -$1.01M -40,915 -0.6%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$144M -$12.9M -521,151 -8%
DM
4
Deerfield Management
New York
$86.7M +$14.4M +583,942 +19%
Vanguard Group
5
Vanguard Group
Pennsylvania
$85.8M +$3.51M +142,286 +4%
BFA
6
BlackRock Fund Advisors
California
$46M -$903K -36,578 -2%
State Street
7
State Street
Massachusetts
$37.3M -$3.47M -140,395 -8%
RG
8
Redmile Group
California
$34.6M +$14.2M +576,930 +65%
BIT
9
BlackRock Institutional Trust
California
$31.9M -$3.35M -135,776 -9%
JP Morgan Chase
10
JP Morgan Chase
New York
$31M +$347K +14,072 +1%
SAM
11
Sectoral Asset Management
Quebec, Canada
$29M -$8.98M -363,657 -23%
Millennium Management
12
Millennium Management
New York
$22.3M +$11.1M +449,714 +91%
PAMU
13
Pictet Asset Management (UK)
United Kingdom
$18.8M +$15M +607,141 +794%
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$15.2M +$123K +5,000 +0.8%
EA
15
Emerald Advisers
Pennsylvania
$15.1M +$7.45M +301,550 +89%
EMFAT
16
Emerald Mutual Fund Advisers Trust
Pennsylvania
$15M +$4.92M +199,162 +46%
Northern Trust
17
Northern Trust
Illinois
$14.2M -$68.3K -2,767 -0.5%
PA
18
Pinnacle Associates
New York
$13.8M +$14.4M +584,406 New
Franklin Resources
19
Franklin Resources
California
$13.6M -$18.3M -739,494 -56%
Deutsche Bank
20
Deutsche Bank
Germany
$12.9M +$902K +36,547 +7%
EAM
21
Eagle Asset Management
Florida
$11.4M -$5.39M -218,228 -31%
GH
22
GAM Holding
Switzerland
$10.8M +$5.11M +207,089 +82%
Wells Fargo
23
Wells Fargo
California
$9.88M +$1.55M +62,965 +18%
VOYA Investment Management
24
VOYA Investment Management
Georgia
$9.79M +$1.44M +58,130 +16%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$9.75M +$350K +14,181 +4%

PTLA Hedge Fund Activity: Q2 2016 in Review

159 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q2 2016, worth a combined $1.24B — up 15% from $1.08B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of PTLA and 22 opened new positions — a net loss of 6 holders — while 46 trimmed existing stakes and 64 added.

The largest buyer was Pictet Asset Management (UK), adding an estimated $15M. The largest seller was Franklin Resources, cutting an estimated $18.3M.

  • 159 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q2 2016, down from 167 in Q1 2016.
  • Funds reported $1.24B of Portola Pharmaceuticals, Inc. stock for Q2 2016, up 15% quarter-over-quarter.
  • 22 funds opened new Portola Pharmaceuticals, Inc. positions in Q2 2016 and 28 closed out, a net change of -6 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q2 2016 was Pictet Asset Management (UK), an estimated $15M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q2 2016 was Franklin Resources, an estimated $18.3M sold.

Based on aggregated 13F filings for Q2 2016.